Who is sponsoring NCT00277472?

NCT00277472 is sponsored by Novartis.

What condition does NCT00277472 study?

NCT00277472 studies Hypertension.

What drugs are being tested in NCT00277472?

Interventions: Valsartan/Hydrochlorothiazide, HCTZ.

What is the status of NCT00277472?

NCT00277472 is currently COMPLETED.

Last reviewed 2011-06-06 · How we verify

A 28-week, Multicenter Study to Evaluate the Effects of Valsartan/Hydrochlorothiazide (160/12.5 mg) in Comparison With Hydrochlorothiazide (25 mg) Monotherapy, for the Treatment of Patients With Hypertension, Uncontrolled by Hydrochlorothiazide (12.5 mg) Monotherapy

NCT00277472 Phase 4 COMPLETED

This study will assess the efficacy and safety of valsartan/hydrochlorothiazide combination therapy in patients with hypertension not controlled with hydrochlorothiazide monotherapy.

Details

Lead sponsor	Novartis
Phase	Phase 4
Status	COMPLETED
Enrolment	300
Start date	2005-11

Conditions

Hypertension

Interventions

Valsartan/Hydrochlorothiazide
HCTZ

Primary outcomes

Blood pressure control (systolic blood pressure <140 and diastolic blood pressure <90mmHg) after 4 weeks
Blood pressure control (systolic blood pressure <140 and diastolic blood pressure <90mmHg) after 2 weeks and 20 weeks

Countries

United States